News Odyssey Therapeutics $168 million Series B financing oversub... Biotech company Odyssey Therapeutics, Inc.
News NICE turns down Takeda colorectal cancer drug Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.
